LOESTRIN 21 1/20 Drug Patent Profile
✉ Email this page to a colleague
When do Loestrin 21 1/20 patents expire, and when can generic versions of Loestrin 21 1/20 launch?
Loestrin 21 1/20 is a drug marketed by Teva Branded Pharm and is included in one NDA.
The generic ingredient in LOESTRIN 21 1/20 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
Summary for LOESTRIN 21 1/20
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Clinical Trials: | 7 |
Patent Applications: | 172 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LOESTRIN 21 1/20 at DailyMed |
Recent Clinical Trials for LOESTRIN 21 1/20
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bristol-Myers Squibb | Phase 1 |
Eisai Inc. | Phase 1 |
Purdue Pharma LP | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for LOESTRIN 21 1/20
US Patents and Regulatory Information for LOESTRIN 21 1/20
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | LOESTRIN 21 1/20 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-21 | 017876-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |